France· FR:67587245
MILNACIPRAN ARROW 50 mg, gélule
A milnacipran product containing chlorhydrate de milnacipran, registered in France by ARROW GENERIQUES, on the national reimbursement list. The same ATC class is registered in 6 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Milnacipran is registered in 6 of 19 countries.
Countries holding a registration under ATC N06AX17 (milnacipran), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 3 of them publish a price we can compare per daily dose
Milnacipran · ATC N06AX17
6 / 19 countries
- Finlandprice
- Franceprice
- Germany
- Japan
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of milnacipran costs, country by country.
Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Milnacipran · price per daily dose (0.1 g)
USD · FX 28 Sept 2026
- US United States$24.47 (acquisition cost)
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CHLORHYDRATE DE MILNACIPRAN
- Manufacturer
- ARROW GENERIQUES
- Country
- France (FR)
- ATC code
- N06AX17
- ATC class
- Milnacipran
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip133400941714313plaquette(s) thermoformée(s) PVC-Aluminium de 56 gélule(s)EUR 5.04
- cip133400941801341plaquette(s) thermoformée(s) PVC PVDC aluminium de 56 gélule(s)EUR 7.05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
194 interactions on record for milnacipran.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Milnacipran · interactions on record
194 records
- 27 severe
- 167 moderate
Most severe, free to view
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- DolasetronA04AA04severe
- PalonosetronA04AA05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Milnacipran in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandIxelParanova Oy
- United KingdomMilnacipran 50mg capsulesSpecial Order
- United StatesMilnacipran HClAmneal Pharmaceuticals LLC
- GermanyMilnacipran GlenmarkGlenmark Arzneimittel Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Austria · Milnacipran Glenmark, Milnacipran Rivopharm
- Germany · Milnacipran Glenmark, Milnacipran Holsten
- Luxembourg · Milnacipran Micro Labs
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e4efe62c-1632-4f68-81e8-4955e87bf41f GET /v1/drugs/e4efe62c-1632-4f68-81e8-4955e87bf41f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67587245",
"date_amm": "2011-06-01",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "CHLORHYDRATE DE MILNACIPRAN",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about milnacipran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.